## 2 Materials and Methods
Bus Scale: National Health and Medical Research Council (NIMRG) [17]
* BLK (“Gusamm, Basel, Switzerland), Palago®: Pruna Riso®: (Keywords Dental, Burlington, MA, USA), Rhodoriza®: (Bchiorioriorne implants, Birmingham, MA, USA), NeobdArcep®: (“Social Bioenzo, Zurich, Switzerland \begin{table}
\begin{tabular}{c c c c c c c c c c c} \hline \hline
**Author and Year of Publication** & **Patients** & **Impl. (CG)** & **Impl. (DG)** & **Porenthesis** & **Survival** & **Application** & **Marginal Bone Loss** & **Scanning/Impression** & **Technical/Wideological** & **Complications** \\ \hline [PERSON] et al., 2019 [4] & 50 & 150 & 150 & 50 & 100\% & 100\% & DC (1.1 + 0.54\(\pm\) CG & DC (685.9 \(\pm\) 2.46) + CG (0/25), DC (0/25) \\ \(\frac{\text{Cattoni}}{\text{2021}}\) & 50 & 100 & 100 & 50 & 100\% & 100\% & DC (0.1 \(\pm\) 0.56), \(p\) \(\pm\) 0.05 & DC (0/25) \\ \(\frac{\text{Cattoni}}{\text{2021}}\) & 50 & 100 & 100 & 50 & \begin{tabular}{c} CC (2/100) \\ implanes - 98\%) \\ \end{tabular} & 100\% & 100\% & DC (0.83 \(\pm\) 0.11), CC (1.2 \(\pm\) 0.26), \(p\) \(\pm\) 0.000 & NR & \begin{tabular}{c} IRol: CC (3, DC = 0. Techn.: \\ CC = 8, DC = 4 \\ \end{tabular} \\ \hline [PERSON] et al., 2010 [1] & 16 & 83 & 83 & NR & NR & 100\% & NR & NR \\ \hline [PERSON] et al., 2024 [5] & 28 & 84 & 84 & 28 & \begin{tabular}{c} 100\% (implicit) \\ Proof - 5/2 \\ DC - 7/4 \\ \end{tabular} & NR & \begin{tabular}{c} CC (1.2 \(\pm\) 0.016) \\ DC (1.4 \(\pm\) 0.02) \\ \end{tabular} & NR & \begin{tabular}{c} CC (10\%), DC (12) \\ - 2M \\ \end{tabular} \\ \hline [PERSON] et al., 2024 [5] & 36 & 36 & 36 & 36 & NR & \begin{tabular}{c} CC = DC ** \\ \end{tabular} & NR & NR & NR \\ \hline [PERSON] et al., 2015 [6] & 14 & NR & 56 & 14 & 100\% & 100\% & \begin{tabular}{c} MC (1.07 \(\pm\) 0.99, A) \\ Mo (1.0 \(\pm\) 0.27 A) \\ Mo (1.0 \(\pm\) 0.81 A) \\ Mo (1.1 \(\pm\) 0.89 B) \\ \end{tabular} & NR & \begin{tabular}{c} NR \\ \end{tabular} & 0 \\ \hline [PERSON] et al., 2016 [6] & 25 & 60 & 60 & 30 & 100\% & \begin{tabular}{c} DC (1.03 \(\pm\) 0.66 A) \\ CG (1.08 \(\pm\) 0.77 A) \\ (1.09 \(\pm\) 0.32 Tiled) \\ \end{tabular} & \begin{tabular}{c} DC \\ (0.77 \(\pm\) 3.09) \(\pm\) 0.65 \\ (1.82 \(\pm\) 5.38) \\ (\(\pm\) 0.05) \\ \end{tabular} & CC (1.75), DC(0/15) \\ \hline [PERSON] et al., 2023 [23] & 29 & NR & 203 & 37 & 100\% & 100 & -5.00 mm & NR & \begin{tabular}{c} Per-impliant mucositis \\ (n = 1) after snounts; \\ Arizona concentration \\ (n = 1), zirconia fracture \\ (n = 1) \\ \end{tabular} \\ \hline [PERSON] et al., 2019 [7] & 15 & NR & 60 & 15 & 100\% & 80\% & NR & NR & \begin{tabular}{c} Adaptation (3/15) \\ per- (1/15) \\ fractured bond (2/15) \\ \end{tabular} \\ \hline [PERSON] et al., 2023 [24] & 27 & 121 Max. & 83 Max. & 36 & NR & \begin{tabular}{c} NR \\ \end{tabular} & NR & NR & \
\begin{tabular}{c} NR \\ \end{tabular} \\ \hline [PERSON] et al., 2023 [25] & 35 & NR & 245 & 45 & NR & 86.70\% & NR & NR &
\begin{tabular}{c} Adap. scan body puligonal \\ Adap. scan body cylindrical \\ 100\% (25/25) \\ \end{tabular} \\ \hline \hline \end{tabular}  
\end{table} 
Table 2: Data for quantitative synthesis of selected articles. The random effects model was adopted for all statistical analyses. Heterogeneity was considered significant for \(p<0.1\). Heterogeneity was assessed using the Q (\(\chi^{2}\)) method, and the I\({}^{2}\) value will be measured. The I\({}^{2}\) statistical value was used to analyze the heterogeneity variations, and I\({}^{2}\) above 75 (0-100) was considered to indicate relevant heterogeneity [26; 27; 28]. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tool was utilized to assess the certainty of evidence for the outcome analyzed. The domains evaluated were risk of bias, inconsistency, indirectness, imprecision, and publication bias. These variables were categorized as high, moderate, low, and very low, providing a nuanced understanding of the evidence. The findings were then compiled and summarized using the GRADEpro Guidance Development Tool (www.gradepro.org).